In summary, in our study, BET inhibition by BAY 1238097 showed remarkable efficacy against NSCLC and PDAC in vivo, significantly reducing tumor burden in genetic mouse models of KRAS-driven tumors. This evidence concerns the gene KRAS and neoplasm.